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Abstract
Background: Epidemiologic studies suggest that long term low dose celecoxib use significantly
lowers breast cancer risk. We previously demonstrated that 400 mg celecoxib taken twice daily
for 2 weeks lowered circulating plasma and breast nipple aspirate fluid (NAF) prostaglandin (PG)E2
concentrations in post- but not premenopausal high risk women. We hypothesized that circulating
concentrations of celecoxib influenced PGE2 response, and that plasma levels of the drug are
influenced by menopausal status. To address these hypotheses, the aims of the study were to
determine: 1) if circulating plasma concentrations of celecoxib correlated with the change in plasma
or NAF PGE2 concentrations from baseline to end of treatment, and 2) whether menopausal status
influenced circulating levels of celecoxib.
Methods:  Matched NAF and plasma were collected from 46 high risk women who were
administered celecoxib twice daily for two weeks, 20 subjects receiving 200 mg and 26 subjects
400 mg of the agent. NAF and plasma samples were collected before and 2 weeks after taking
celecoxib.
Results: In women taking 400 mg bid celecoxib, plasma concentrations of the agent correlated
inversely with the change in NAF PGE2 levels from pre- to posttreatment. Nonsignificant trends
toward higher celecoxib levels were observed in post- compared to premenopausal women. There
was a significant decrease in NAF but not plasma PGE2 concentrations in postmenopausal women
who took 400 mg celecoxib (p = 0.03).
Conclusion: In high risk women taking 400 mg celecoxib twice daily, plasma concentrations of
celecoxib correlated with downregulation of PGE2  production by breast tissue. Strategies
synergistic with celecoxib to downregulate PGE2 are of interest, in order to minimize the celecoxib
dose required to have an effect.
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Background
Cyclooxygenases (COX)-1 and COX-2 may be present in
breast tumors to catalyze the conversion of arachidonic
acid to prostaglandins, prostacyclins, or thromboxanes.
While COX-1 expression is constitutive, COX-2 is induci-
ble [1] and is upregulated in a variety of tumors, including
breast cancers [2]. Prostaglandin (PG)E2, which has tumor
and cell growth promoting activity [3], is produced from
arachidonic acid by either COX-1 or -2. Malignant breast
tumors produce more PGE2 than benign breast tumors or
normal breast tissue [2]. Women with breast cancer with
TUMOR PGE2 levels above 15 ng/g appear to have a sig-
nificantly worse survival rate than those with levels ≤ 15
ng/g [4].
Nonsteroidal antiinflammatory drugs (NSAIDs), includ-
ing aspirin, indomethacin and ibuprofen, inhibit both
COX-1 and COX-2. Inhibition of COX-1 leads to a
number of adverse effects, including gastrointestinal
ulcers and renal toxicity [5]. Recent efforts have therefore
focused on pharmacologic agents such as celecoxib, a clin-
ically available medication which selectively inhibits
COX-2. Preclinical and epidemiologic studies suggest that
celecoxib is effective both in preventing and in treating
breast cancer in a dose dependant manner [6-9]. A case
control study of women with and without breast cancer
who were evaluated during a 12 month period found that
women who had used 200 mg celecoxib daily for 2 years
or longer were 83% less likely to be diagnosed with breast
cancer than were controls [8]. Two international, multi-
center studies using celecoxib to prevent sporadic colorec-
tal adenomas were recently reported, the Adenoma
Prevention with Celecoxib (APC) and the Prevention of
Colorectal Sporadic Adenomatous Polyps (PreSAP) trials.
Both demonstrated the efficacy of celecoxib in preventing
colorectal adenomas after three years of treatment. Com-
pared to placebo, the APC, but not PreSAP study, demon-
strated an increased risk of cardiovascular events in the
celecoxib arm. The APC study administered celecoxib 200
or 400 mg bid, whereas the PreSAP study was a single
daily 400 mg dose. Mean plasma concentrations of
celecoxib were not measured in either study.
Circulating celecoxib concentrations have been measured
in preclinical treatment and in pharmacokinetic human
trials. Improved survival of mice with erythroleukemia
was demonstrated by a combination of low dose vincris-
tine [10] in combination with a dose of celecoxib which
provided average circulating celecoxib concentrations of
2198 ng/mL (5.77 μM). Circulating concentrations of 876
ng/mL (2.3 μM) celecoxib slowed the growth of HCA-7
human colorectal cancer xenografts in nude mice [11].
The half life of celecoxib averages 11 hours in fasting
patients [12]. Adminstration of 400 mg celecoxib daily to
68 healthy adults for 2 weeks, with the time from last dose
to blood collection ranging from 9–24 hrs, led to a mean
plasma concentration of 607 +/- 338 ng/ml (range
82–1700 ng/mL) [13].
We are currently able to collect breast nipple aspirate fluid
(NAF) from 95% of nonlactating adult females with the
use of a modified breast pump [14]. Median PGE2 concen-
trations in NAF were 55 times higher than in matched
plasma prior to treatment with celecoxib [15]. We found
that 400 mg twice daily (bid) of the COX-2 inhibitor
celecoxib administered for two weeks to women at
increased breast cancer risk significantly decreased PGE2
levels in the breast, as measured both in NAF and in
plasma [16]. We sought to extend these findings to deter-
mine: 1) if circulating concentrations of celecoxib corre-
lated with change in plasma or NAF PGE2 from baseline to
end of treatment, and 2) whether menopausal status
influenced circulating concentrations of celecoxib. We
observed that the circulating plasma concentration of
celecoxib was related to the reduction in PGE2 in NAF but
not in plasma at the end of celecoxib therapy in high risk
women receiving 400 mg celecoxib twice daily.
Methods
Subject recruitment
Women were provided an Institutional Review Board
approved protocol and required to give written informed
consent in order to enroll in the study. Subjects evaluated
had to be ≥ 18 years old and be at increased breast cancer
risk, based on the subject having either a Gail model risk
of developing invasive breast cancer (IBC) in a 5 year
period of > 1.66%, or previously treated ductal carcinoma
in situ (DCIS) or IBC (now finished with treatment and
free of disease).
Pregnant and lactating women were not eligible. Women
could not have been currently on NSAIDs, aspirin, a COX-
2 inhibitor, warfarin, or have taken such a medication
within two weeks of enrollment. Subjects could not have
a significant history of peptic ulcer disease, upper gas-
trointestinal bleeding, asthma, or be allergic to sulfona-
mides or NSAIDs. A complete blood count, serum
electrolytes and liver panel had to be within normal lim-
its. Subjects were recruited from the Breast Evaluation
Clinics at the University of Missouri-Columbia.
Intervention
Celecoxib pills were taken bid for 14 days. Compliance
was assessed through the count of returned pills. All sub-
jects were required to have taken at least 80% of the pre-
scribed medication. The first 20 subjects recruited received
20 mg celecoxib twice daily. Analysis of the data from
these subjects did not demonstrate a significant downreg-
ulation of pge2 in any subgroup. All subsequent subjects
recruited received 40 mg celecoxib twice daily.BMC Cancer 2008, 8:49 http://www.biomedcentral.com/1471-2407/8/49
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Specimen collection
NAF was collected using a modified breast pump as previ-
ously described [14,17]. Briefly, the breast was warmed
with moist heated towels for 5–10 minutes, subsequently
massaged from the chest wall toward the nipple while a
health care professional provided suction using a modi-
fied breast pump. The sample was collected into capillary
tubes and stored at -80°c until analysis. NAF volume was
measured using a metric ruler. We have determined that
one mm in the tube corresponds to approximately one μL
OF NAF. NAF was collected from only one breast, and
NAF from the same breast was analyzed before and after
treatment.
Baseline NAF and blood collection were performed prior
to the ingestion of celecoxib. Eight mL of blood were also
collected from the subject in a tube containing heparin,
the blood spun for 10 min at 1600 rpm, and the plasma
fraction decanted and stored at -80°C until analysis. All
women had NAF and plasma collected within 24 hrs of
their last dose of celecoxib, with an average of approxi-
mately 12 hrs. The half life of the medication is 11.5 hrs.
Specimen analysis
PGE2
The biomarker chosen for analysis was PGE2, due to its
established link to cancer growth. NAF and plasma sam-
ples were analyzed by immunoassay for their PGE2 con-
tent as per the manufacturer's instructions (R&D Systems,
Minneapolis, MN). The kit uses a monoclonal antibody to
PGE2 to competitively bind the PGE2 in the standard or
sample. Briefly, samples were diluted in 100 μL assay
buffer supplied by the manufacturer, pipetted into appro-
priate wells, incubated for 18–24 hrs at 4°C, washed, sub-
strate solution added, followed by one hr incubation, and
absorbance measured at 405 nm.
For NAF and plasma analyses, a standard curve was pre-
pared using serial dilutions of PGE2. A linear regression
equation was created from standards of known PGE2 con-
centration, and PGE2 concentrations of unknown samples
fit to the standard curve regression equation, corrected for
aliquot volume and expressed as nanograms of PGE2/mL
of original sample. Whenever possible, NAF and plasma
samples were run in duplicate and the average of the two
values was reported. The goodness of fit of the standard
curve, R2, for NAF samples was 0.999. The goodness of fit
was similar for the plasma samples.
Celecoxib
Celecoxib was analyzed in plasma using a modification of
the technique of Schonberger et al. [18] by combining
250 μL aliquots of plasma with an equal volume of dis-
tilled water and adding 500 uL ethanol to precipitate pro-
tein. Spiked plasma samples were prepared by combining
250 μL blank plasma with 250 μl distilled water, 20 μL of
10 ppm celecoxib in ethanol and 480 μL of ethanol. Sam-
ples were vortexed and then centrifuged at 13,000 rpm for
5 min. A 500 uL aliquot of the supernatant was combined
with 1.5 mL distilled water and applied to a Waters 3 mL
C18 Sep-Pac-Vac disposable cleanup column (Waters, Mil-
ford, MA) which was preconditioned with 2 mL methanol
and then 2 mL distilled water. Cleanup columns were
washed with 2 mL distilled water and vacuum dried for 15
minutes. Celecoxib was eluted with 4 mL methanol and
the sample eluants taken to dryness. Samples were recon-
stituted in 1.0 mL methanol:water (80:20) for HPLC anal-
ysis.
HPLC analysis was performed on an Hitachi HPLC system
(Hitachi Instruments, Inc., San Jose, CA) which consisted
of an L7100 pump, with an L7200 autosampler (20 ul
injected), and fluorescence detection with an L7480 fluo-
rescence detector (excitation 240 nm, emission 380 nm).
The system was controlled, data acquired and processed
using an Hitachi D-7000 data acquisition package with
Concert Chrom software on a microcomputer. A Phenom-
enex Hypersil BDS C18 analytical column (250 × 4.6 mm,
5 um) (Phenomenex, Torrence, CA) and a Phenomenex
Securityguard C18 precolumn with a mobile phase of ace-
tonitrile:water (70:30) was used at a flow rate of 1 mL/
min. Celecoxib was kindly provided by Pfizer Corpora-
tion, New York, NY. A primary standard of celecoxib
(2,000 ppm) was prepared in acetonitrile. Working stand-
ards (100, 200, 500 ppb) were prepared in metha-
nol:water (80:20). Plasma samples spiked with celecoxib
had recoveries greater than 95%.
Each sample batch that was run included a serum sample
spiked with 200 ng/mL celecoxib to assess the recovery
rate of the assay. The recovery rate was 99.5% +/- 3.4% (n
= 11). In addition to assessing the recovery rate, we ran-
domly selected 11 post treatment samples for duplicate
analyses. We also analyzed six serum samples in duplicate
that were collected before the subject started celecoxib.
Each of the six baseline serum samples demonstrated zero
values at both runs. The 11 post treatment samples each
had measurable celecoxib levels, with the deviation
within each set of these 11 samples having a CV < 10%.
Toxicity
Among women taking celecoxib 200 mg bid, two subjects
experienced side effects (one nausea, the second a cough),
with both resolving spontaneously. There were no drop-
outs in the 200 mg bid group. Among women enrolled in
the 400 mg bid group, 11 experienced side effects from
celecoxib, four of whom dropped out. Of the four who
dropped out, the side effects (edema in two, diarrhea in
one, and heart palpitations in one) resolved shortly after
stopping celecoxib. Among the remaining seven subjects,BMC Cancer 2008, 8:49 http://www.biomedcentral.com/1471-2407/8/49
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the side effects: diarrhea, nausea, rash, altered taste, uri-
nary urgency, sweating, and muscle tension, all resolved
spontaneously.
Statistical analysis
Median values of continuous variables were computed for
the various groups of subjects. Due to the potential non-
normality of the data, ranking procedures were used for
all analyses with continuous variables. The Wilcoxon
Rank Sum Test was used to compare independent groups.
Examples of these comparisons include comparing pre-
and postmenopausal women, etc. The Wilcoxon Signed
Ranks Test was used to make within group comparisons
such as comparing pretreatment to posttreatment. Spear-
man's Correlation Coefficients were used to correlate
quantitative variables such as age and celecoxib levels.
Results
Subjects
Between October 2001 and December 2004, informed
consent was obtained from 54 women at increased breast
cancer risk to enroll in an institutional review board
approved protocol. Of the 54, 22 initiated celecoxib 200
mg bid and 32 celecoxib 400 mg bid. Two of the 54 (one
in each dosage group) were not evaluable because plasma
was not collected after treatment, preventing the measure-
ment of celecoxib. Early in the study, two additional
women (one in each dosage group) were excluded
because we did not collect NAF from the same breast at
baseline and after treatment. Later in the study we allowed
the assessment of women who had plasma collected at
both time points, even if matched NAF was not available,
since we could still evaluate the association of circulating
celecoxib concentrations with the systemic PGE2
response. Four additional subjects dropped out due to
side effects, all in the 400 mg bid group, leaving 46 evalu-
able subjects. Side effects are discussed in greater detail
below.
All 46 subjects provided NAF at their baseline visit. Rea-
sons for not collecting NAF in 5 women at their follow-up
visit included: one woman refused, in two women
attempts to collect NAF were unsuccessful, and two
women yielded less than one microliter of NAF, which we
felt was insufficient for reliable analysis of PGE2 (Table 1).
Plasma was collected in all subjects at all visits. In total, 41
matched NAF and 46 matched blood samples were col-
lected at baseline and after two weeks of celecoxib treat-
ment from 46 subjects.
Half of the evaluable subjects in the 400 mg group, and
30% in the 200 mg group, were premenopausal. All but
one subject recruited was Caucasian. In both dosage
groups, the median number of celecoxib pills taken was
over 98%, and all subjects took over 80% of the pills that
they were given.
Celecoxib concentrations in ng/mL
At the end of treatment, celecoxib was detectable in the
plasma of 16 of 20 participants (80%) in the 200 mg
group, and 20 of 26 participants (77%) in the 400 mg
group. The limit of detection of the assay was 100 ng/mL.
Of samples in which celecoxib was detectable, values
ranged from 117.6 to 2281.2 ng/mL in the 200 mg group
and from 156.8 to 16403.1 ng/mL in the 400 mg group.
Table 1: Demographics
Celecoxib Dose
200 mg twice daily 400 mg twice daily
NAF (plasma) NAF(plasma)
Samples 19 (20) 22 (260
Age (years)
Median 48 (47) 50.5 (50.5)
Range 23–68 (23–68) 30–81 (30–81)
Premenopausal 5 (6) 11 (11)
Race
White 19 (20) 40 (45)
Black 0 0
Asian 0 0
American Indian 0 1 (1)
Primary Risk Factors for Enrollment
Family History 11 (11) 14 (17)
Hyperplasia with/without atypia 3 (3) 6 (6)
History of Breast Cancer 3 (3) 3 (3)
History Prior Breast Biopsy 2 (3) 0BMC Cancer 2008, 8:49 http://www.biomedcentral.com/1471-2407/8/49
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Levels trended (p = 0.08) higher in women taking 400 mg
compared to 200 mg bid (Table 2).
Celecoxib concentrations at the end of treatment were
compared in pre- and postmenopausal women. Median
concentrations in post- vs premenopausal women in the
200 mg group were: 267.5 ng/mL vs 117.6 ng/mL, and in
the 400 mg group: 860.6 ng/mL vs. 227.3 ng/mL respec-
tively (Table 2). Neither difference reached statistical sig-
nificance (low dose, p = 0.26; high dose, p = 0.14).
Celecoxib concentrations are associated with the decrease 
in PGE2 concentration in NAF but not plasma from high 
risk women taking high dose celecoxib
We compared plasma concentrations of celecoxib at the
end of treatment with the change in NAF PGE2 from sam-
ples collected before and at the end of treatment.
Celecoxib concentrations were significantly related (p =
0.006, r = -0.57) to the change in PGE2 in women taking
400 mg bid (Table 2) but not 200 mg bid celecoxib. The
reason for high risk designation did not significantly
influence a subject's PGE2 response to celecoxib.
Plasma celecoxib concentrations at the end of treatment
were next compared to the change in PGE2 concentrations
in plasma (Table 3). Unlike NAF, there was no association
between celecoxib concentrations and the change in
plasma PGE2 concentrations in high risk women taking
400 mg bid, nor in high risk women taking 200 mg bid.
At both the 200 mg and 400 mg doses of celecoxib,
plasma concentrations of the drug trended lower in pre-
than postmenopausal women. We therefore determined if
there was a difference in the PGE2 response to celecoxib in
NAF and/or plasma based on menopausal status (Figure
1). In the 400 mg group, the correlation coefficient was
similar in both pre- (r = -0.52) and postmenopausal (r = -
0.49) women (Figure 1C, D). Nonetheless, a significant
decrease in NAF PGE2 was only observed in postmeno-
pausal women (Table 2).
Discussion
The objectives of the present study were to determine
whether plasma celecoxib concentrations correlated with
changes in either plasma or NAF PGE2 concentrations in
women at increased risk for breast cancer, and whether a
woman's pre- or postmenopausal status affected the
plasma celecoxib concentration. This study extends our
previous report that celecoxib treatment decreased PGE2
in NAF but not plasma in postmenopausal high risk
women [16], by examining circulating celecoxib concen-
trations in matched plasma. In the current study, we con-
firmed our original observation that PGE2 levels in NAF,
but not in plasma, decreased after celecoxib treatment in
postmenopausal women, and that the PGE2 response in
NAF correlated with plasma celecoxib concentration at
the 400 mg bid dose level (figure 1). The significant
decrease in NAF PGE2 that was observed in post- but not
premenopausal women is likely because most premeno-
pausal women had low (median 227 ng/ml) celecoxib
levels, whereas most postmenopausal women had higher
(median 860 ng/ml) levels.
Celecoxib concentrations were measured in plasma using
two different dose regimens. Women taking 200 mg of
celecoxib twice daily had a median plasma concentration
Table 2: Median concentrations of PGE2 in NAF and celecoxib in plasma in ng/ml based on celecoxib dose1
Population: Dose Before (N) After (N) After v. P value
Treatment Treatment Before(N)2 ΔPGE2 Celecoxib Level & ΔPGE2
200 mg twice daily
Overall PGE2 13.75(19) 17.78(19) 0.37(19) 0.54 0.29
Celecoxib 223.7(19)
Premenopausal PGE2 13.75(5) 21.85(5) 5.50(5) 0.63
Celecoxib 117.6(5)
Postmenopausal PGE2 14.15(14) 13.79(14) -0.34(14) 0.86
Celecoxib 267.5(14)
400 mg twice daily
Overall PGE2 13.80(22) 13.22(22) -1.72(22) 0.83 0.006
Celecoxib 759.8(22)
Premenopausal PGE2 15.7(11) 36.1(11) 7.31(11) 0.17
Celecoxib 227.3(11)
Postmenopausal PGE2 8.33(11)3 6.81(11) -4.95(11) 0.03
Celecoxib 860.6(11)
1: N: sample size; NAF: nipple aspirate fluid. P values assess ΔPGE2 (was the change from before to after treatment significant) and celecoxib level & 
ΔPGE2 (was the celecoxib level after treatment related to the change in PGE2)
2: Median change in PGE2 levels after treatment.
3: Only matched samples are included in this analysis, unlike the previous report which included PGE2 values for all subjects [16].BMC Cancer 2008, 8:49 http://www.biomedcentral.com/1471-2407/8/49
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of 253 ng/ml. When comparing the median plasma
celecoxib concentration of pre- and postmenopausal
women, a difference was observed (195 vs 267 ng/ml
respectively). However, the difference was not statistically
significant. This difference was also observed in the group
of women taking 400 mg of celecoxib bid. Premenopausal
women taking the higher celecoxib dose had a median
plasma celecoxib concentration of 227 ng/ml while the
postmenopausal women had a median value of 860 ng/
ml. Again, this difference did not reach statistical signifi-
cance, but is suggestive that there may be a relationship
between menopausal status and plasma celecoxib concen-
tration. Average time to collection after last dose was sim-
ilar for both the premenopausal and postmenopausal
subjects. It is possible, therefore, that the higher circulat-
ing concentrations of drug in postmenopausal women
contributed to this greater effect. Although one report in
which most of the enrolled subjects were male did not
find an association of celecoxib level with age [19], it is
possible that in women, menopausal status might influ-
ence the rate of clearance of the agent. The mechanisms of
this possible difference are unclear but the qualitative
observation warrants further investigation.
We are aware of six studies which evaluated steady state
circulating celecoxib levels in humans (Table 4). Three
were in healthy adults of various ages, one in a healthy
elderly population, one in children with cancer, and one
Change in NAF PGE2 relative to plasma celecoxib level based on menopausal status and dose Figure 1
Change in NAF PGE2 relative to plasma celecoxib level based on menopausal status and dose. (A) Premenopau-
sal women who received 200 mg celecoxib bid. (B) Postmenopausal women who received 200 mg celecoxib bid.(C) Premen-
opausal women who received 400 mg celecoxib bid. (D) Postmenopausal women who received 400 mg celecoxib bid. The 
horizontal line in each graph represents no change in PGE2 from pre- to posttreatment. Values above the horizontal line repre-
sent an increase in PGE2 posttreatment, values below a decrease.
Table 3: Median concentrations of PGE2 and celecoxib in plasma in ng/ml based on celecoxib dose1
Population: Dose Before (N) After (N After v. P value
Treatment Treatment Before(N) ΔPGE2 Celecoxib Level & ΔPGE2
200 mg twice daily
Overall PGE2 0.24(20) 0.22(20) -0.003(20) 0.70 0.25
Celecoxib 253.4(20)
Premenopausal PGE2 0.42(6) 0.33(6) 0.008(6) 1.0
Celecoxib 195.3(6)
Postmenopausal PGE2 0.21(14) 0.20(14) -0.004(14) 0.58
Celecoxib 267.5(14)
400 mg twice daily
Overall PGE2 0.29(26) 0.21(26) -0.016(20) 0.72 0.93
Celecoxib 759.8(26)
Premenopausal PGE2 0.37(11) 0.37(11) -0.0005(11) 0.77
Celecoxib 227.3(11)
Postmenopausal PGE2 0.28(15) 0.19(15) -0.037 0.64
Celecoxib 860.6(15)
1: N: sample size; NAF: nipple aspirate fluid. P values assess ΔPGE2 (was the change from before to after treatment significant) and celecoxib level & 
ΔPGE2 (was the celecoxib level after treatment related to the change in PGE2)BMC Cancer 2008, 8:49 http://www.biomedcentral.com/1471-2407/8/49
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in adults with cancer. Sample sizes were generally small,
with four of the six evaluating fewer than 10 subjects.
Time on medication was one or two weeks in five of the
studies. The dose ranged from 200 mg bid to 400 mg bid,
with the pediatric dose adjusted per kg body weight to
match an adult dose of 400 mg bid. Plasma concentra-
tions ranged from 437 to 1087 ng/mL, although levels
within individuals varied more than 100 fold [18]. Thus,
the circulating celecoxib concentrations measured in our
study are consistent with those previously reported in the
literature.
In three of the groups of women (premenopausal @ 200
mg bid, postmenopausal @ 200 mg bid and premeno-
pausal @ 400 mg bid), plasma celecoxib concentrations
ranged between 195 and 267 ng/ml. In contrast, the post-
menopausal women demonstrated a median plasma
celecoxib concentration of 860 ng/mL. There was a strong
inverse correlation both in pre- and postmenopausal
women receiving 400 mg bid celecoxib between plasma
celecoxib concentrations and naf PGE2. It therefore
appears that, regardless of menopausal status, it is the cir-
culating level of celecoxib that is important, with low lev-
els having little influence on PGE2, and higher doses
decreasing PGE2. Although we cannot exclude the possi-
bility that low celecoxib levels increase PGE2, changes in
PGE PGE2 at lower celecoxib levels were not significant.
The lack of effect of celecoxib at either 200 or 400 mg
twice daily on the plasma PGE2 concentration is not unex-
pected. Celecoxib is a specific COX-2 inhibitor and its
clinical advantage is that it does not inhibit COX-1. COX-
1 is assumed to be a constitutively expressed enzyme that
is present in almost every cell of the body. COX-2 is
assumed to be an inducible enzyme that responds to spe-
cific conditions and environments. Since PGE2 is a local
mediator, most of the circulating plasma PGE2 probably
represents COX-1 activity. Since celecoxib specifically
inhibits COX-2, the PGE2 present in NAF is likely the
product of both COX-1 and COX-2 activity, with the
downregulation of PGE2 reflecting the action of celecoxib.
We suspect that the significant decrease (from a median of
8.33 to 6.81 ng/ml) which occurred in the group with the
highest overall celecoxib levels,. Is due to the effect of
celecoxib on PGE2 contributed by COX-2, but not that
contributed by COX-1, which is why levels decreased a
median of 18% rather than to a greater extent.
We observed differences in the overall median plasma
concentration of celecoxib in women receiving a dose of
200 mg bid (224 ng/ml) versus 400 mg bid.(760 ng/ml).
Although no statistically significant differences were seen
in the plasma concentration of celecoxib in pre- versus
postmenopausal women in either dose group, there was a
qualitative trend for higher plasma concentrations in the
postmenopausal group. We also observed a significant
decrease in NAF PGE2 among women taking 400 mg
celecoxib bid for 2 weeks where the median circulating
dose of celecoxib was 860.6 ng/mL, but not in women tak-
ing 200 mg bid, where the median circulating dose was
less than 300 ng/mL. An observational study observed
that long term (at least 2 years) use of low dose (200 mg
daily) celecoxib significantly decreased breast cancer risk
[7]. Our data suggest that in the short term 200 mg bid is
not sufficient to reliably inhibit breast tissue formation of
PGE2, although long-term therapy may.
Celecoxib therapy is associated with cardiovascular risk
and its value as a chemopreventative agent may be called
into question. However, the currently approved breast
cancer chemopreventive agents tamoxifen and raloxifene
have side effects of hot flashes, vaginal discharge, blood
clots and stroke. Tamoxifen also increases the risk of
endometrial carcinoma, endometrial sarcoma and cata-
racts. Aromatase inhibitors, which are under investigation
as breast cancer chemopreventive agents, increase the risk
of osteoporosis. If celecoxib is to ever be used as a chem-
opreventive agent, there is a need to balance breast cancer
risk reduction while minimizing risk of cardiovascular
toxicity, which has only been associated with high dose
Table 4: Studies measuring circulating celecoxib levels
Population Subjects Weeks On Drug Dose (mg)1 Last Dose (hrs)2 Source Celecoxib concentration 
(ng/mL)
Healthy Adults [18] 8 2 200 b.i.d. up to 25 serum 437
Healthy Adults [18] 35 2 40 q.d. 13 plasma 568
Healthy Adults [18] 24 2 200 b.i.d. up to 24 plasma 500
Healthy Adults [20] 35 6 400 q.d. 13 plasma 601
Elderly Adults [21] 8 1 200 b.i.d. 2 plasma 755
Pediatric cancer patients [22] 9 250 mg/kg b.i.d. 6 plasma 668
Adult cancer patients [23] 4 week3 400 b.i.d. 6–8 plasma 1087
1: b.i.d.: twice daily; q.d.: once daily
2: Unless otherwise stated, average time from last dose celecoxib to blood draw
3: The text did not define how many weeks the subjects took the medicationBMC Cancer 2008, 8:49 http://www.biomedcentral.com/1471-2407/8/49
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celecoxib. It is important to determine an optimal
celecoxib dose which minimizes toxicity while conferring
a cancer protective effect. Under these conditions,
celecoxib may prove to be a valuable chemopreventive
agent.
In conclusion, our findings suggest that monitoring
plasma celecoxib concentrations may provide a method
to determine response to a an intermediate marker of
breast cancer. Long term studies are needed to assess if
plasma celecoxib concentrations will predict the breast
cancer preventive effect of the agent.
Conclusion
In this short term study, plasma concentrations of
celecoxib correlated with downregulation of PGE2 pro-
duction by breast tissue in women taking 400 mg bid, but
not the 200 mg bid dose. Given epidemiologic studies in
breast cancer suggesting a chemopreventive effect of lower
doses after longer term use, prospective studies using
lower doses, as well as chemoprevention strategies syner-
gistic with celecoxib to downregulate PGE2 are of interest,
in order to minimize the celecoxib dose required to have
an effect.
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